First Department of Clinical Medicine, Shanxi Medical University, Key Laboratory of Cellular Physiology at Shanxi Medical University, Ministry of Education, Shanxi Province, China.
Department of Cardiology, The 1st Hospital of Shanxi Medical University, Key Laboratory of Cellular Physiology at Shanxi Medical University, Ministry of Education, Shanxi Province, China.
Medicine (Baltimore). 2022 Sep 9;101(36):e30310. doi: 10.1097/MD.0000000000030310.
Sodium-glucose cotransporter 2 inhibitor (SGLT2I) is a new type of hypoglycemic drug that targets the kidney. As research continues to advance on this topic, it has been found that SGLT2I has multiple protective effects, such as hypoglycemic, cardio-renal protective, antihypertensive, and lipid-lowering effects. This review discusses the current concepts and possible mechanisms of SGLT2I in the treatment of heart failure, myocardial infarction, hypertension, cardiomyopathy and arrhythmia to provide a reference for clinicians to use drugs more reasonably and scientifically.
钠-葡萄糖共转运蛋白 2 抑制剂（SGLT2I）是一种针对肾脏的新型降糖药物。随着对该领域研究的不断深入，发现 SGLT2I 具有多种保护作用，如降糖、心肾保护、降压和调脂作用。本文就 SGLT2I 治疗心力衰竭、心肌梗死、高血压、心肌病和心律失常的相关新概念和可能机制进行综述，为临床医生更合理、更科学地使用药物提供参考。
